ERα degrader / Relay Therap, Revolution Medicines - LARVOL DELTA

Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights (Yahoo News) - "RLY-4008: Full dose escalation data in the first half of 2023; Complete enrollment of pivotal cohort in the second half of 2023; Data from non-CCA expansion cohorts in the second half of 2023; Breast Cancer; RLY-2608: initial clinical data from dose escalation portions of monotherapy and combination arms of trial in the first half of 2023; RLY-5836: clinical start in the second quarter of 2023; ERα degrader: development candidate nomination in 2023; Selective CDK2 inhibitor: clinical start in early 2024..."

Enrollment status • New trial • P1 data • P1/2 data • Pipeline update • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor